AU2008253667A1 - Treatment of allergic disease with immunomodulator compounds - Google Patents

Treatment of allergic disease with immunomodulator compounds Download PDF

Info

Publication number
AU2008253667A1
AU2008253667A1 AU2008253667A AU2008253667A AU2008253667A1 AU 2008253667 A1 AU2008253667 A1 AU 2008253667A1 AU 2008253667 A AU2008253667 A AU 2008253667A AU 2008253667 A AU2008253667 A AU 2008253667A AU 2008253667 A1 AU2008253667 A1 AU 2008253667A1
Authority
AU
Australia
Prior art keywords
scv
ova
animals
treatment
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008253667A
Other languages
English (en)
Inventor
Alexandr A. Kolobov
Andrey S. Simbirtsev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of AU2008253667A1 publication Critical patent/AU2008253667A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008253667A 2007-05-17 2008-05-13 Treatment of allergic disease with immunomodulator compounds Abandoned AU2008253667A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2007118237/14A RU2007118237A (ru) 2007-05-17 2007-05-17 Способ лечения аллергических заболеваний
RU2007118237 2007-05-17
US95720107P 2007-08-22 2007-08-22
US60/957,201 2007-08-22
PCT/US2008/006072 WO2008143824A1 (en) 2007-05-17 2008-05-13 Treatment of allergic disease with immunomodulator compounds

Publications (1)

Publication Number Publication Date
AU2008253667A1 true AU2008253667A1 (en) 2008-11-27

Family

ID=40122024

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008253667A Abandoned AU2008253667A1 (en) 2007-05-17 2008-05-13 Treatment of allergic disease with immunomodulator compounds

Country Status (14)

Country Link
US (1) US20100204295A1 (https=)
EP (1) EP2164507B1 (https=)
JP (1) JP2010527354A (https=)
KR (1) KR20100022044A (https=)
CN (1) CN101678069A (https=)
AU (1) AU2008253667A1 (https=)
BR (1) BRPI0811572A2 (https=)
CA (1) CA2684046A1 (https=)
IL (1) IL202114A0 (https=)
MX (1) MX2009012297A (https=)
NZ (1) NZ581748A (https=)
RU (1) RU2007118237A (https=)
UA (1) UA100018C2 (https=)
WO (1) WO2008143824A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090119897A (ko) * 2007-02-13 2009-11-20 사이클론 파아머슈티컬 인코오퍼레이티드 점막의 질환으로 인한 조직 악화, 상처 또는 손상을 치료 또는 예방하는 방법
RU2635968C1 (ru) * 2016-11-17 2017-11-17 Аллан Герович Бениашвили Способ лечения и профилактики состояний аллергического спектра
KR102633086B1 (ko) * 2018-11-12 2024-02-05 씨제이제일제당 주식회사 N-아세틸-l-트립토판을 유효성분으로 포함하는 젖소용 사료첨가제
WO2020242133A1 (ko) * 2019-05-24 2020-12-03 전북대학교 산학협력단 N-아실-아미노산을 유효성분으로 포함하는 천식, 비염 또는 결막염의 예방 또는 치료용 조성물
KR102376756B1 (ko) * 2019-05-24 2022-03-21 주식회사 스템디알 N-아실-아미노산을 유효성분으로 포함하는 천식, 비염 또는 결막염의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
SU1544438A1 (ru) 1988-04-04 1990-02-23 Научно-исследовательский институт онкологии им.проф.Н.Н.Петрова Способ плазмосорбции
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
US5811399A (en) * 1988-12-14 1998-09-22 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US7173013B2 (en) * 2001-06-08 2007-02-06 Sciclone Pharmaceuticals, Inc. Treatment of tuberculosis using immunomodulator compounds
UA92586C2 (ru) * 2004-05-14 2010-11-25 Сайклон Фармасютикалс, Инк. Лечение или предотвращение респираторных вирусных инфекций с помощью иммуномодуляторов

Also Published As

Publication number Publication date
UA100018C2 (ru) 2012-11-12
KR20100022044A (ko) 2010-02-26
IL202114A0 (en) 2010-06-16
CA2684046A1 (en) 2008-11-27
EP2164507B1 (en) 2012-07-11
NZ581748A (en) 2012-03-30
EP2164507A4 (en) 2011-01-05
BRPI0811572A2 (pt) 2015-07-21
RU2007118237A (ru) 2008-11-27
WO2008143824A1 (en) 2008-11-27
MX2009012297A (es) 2010-02-17
EP2164507A1 (en) 2010-03-24
CN101678069A (zh) 2010-03-24
JP2010527354A (ja) 2010-08-12
US20100204295A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
Maywald et al. Zinc homeostasis and immunosenescence
Idzko et al. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function
US8603978B2 (en) Use of muramyl dipeptide (MDP) for treating inflammation
US8454967B2 (en) Compositions and methods for modulating the immune system
EP2992881B1 (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells
KR20030070092A (ko) 죽상경화증을 예방 및 치료하기 위한 플라크 관련 분자를함유하는 조성물 및 이 분자를 이용하는 방법
CN102573831A (zh) 用于治疗免疫相关病症的去铁胺-金属络合物
EP2164507B1 (en) Treatment of allergic disease with immunomodulator compounds
ES2434039T3 (es) Composiciones farmacéuticas que comprenden ccl2 para su uso en el tratamiento de la inflamación
JP4804626B2 (ja) 免疫レギュレータ
JP2017061449A (ja) ループスの処置のためのプロテアソーム阻害剤デランゾミブ
JP2002503658A (ja) ＣＯＰ−１及びＴｈ−２促進性サイトカインを使用した、多発性硬化症の治療
AU665403B2 (en) Use of ruthenium red for inhibiting immune response
US9383348B2 (en) Compositions and methods for treating lung disorders
CN104958286A (zh) 用于治疗疾病的化合物
US20070161541A1 (en) Insult induced immune dissonance
CN109475549B (zh) 药物组合物及其治疗自身免疫疾病的用途
WO2021161983A1 (en) Novel medicament for treating inflammatory disease
HK1142534A (en) Treatment of allergic disease with immunomodulator compounds
EP4096679A1 (en) Methods of using momelotinib to treat joint inflammation
US20260007640A1 (en) Compositions for the treatment of inflammatory disorders
Slavyanskaya CANCER CHECKPOINT BLOCKADE
TW202402321A (zh) 一種第i型甲醯胜肽受體拮抗劑及其用途
WO2022251824A1 (en) Mmp13 as a therapeutic target for allergic inflammatory diseases
JP2015101585A (ja) 中枢神経系自己免疫疾患治療用のアンジオテンシン変換酵素阻害剤

Legal Events

Date Code Title Description
MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination